Money moves in silence. Download 2025 State of Venture Report: a data-driven analysis of active funds, unicorn, and family offices
About usSign in

Boehringer Ingelheim Venture Fund

WebsiteLinkedInTwittercbCrunchbase
Status
ACTIVE
Global HQ
Paris, France
Countries of investment
  • USA
Investment stages
  • Seed
  • Series A
  • Series B
Industries
  • Health Tech
About
Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies.
Min check size
$500K
Max check size
$1M
Fund size
NPS

Investment Thesis

The Boehringer Ingelheim Venture Fund invests in pioneering science that offers the potential to provide significant benefits for patients, with investments spanning across various geographies.
Lead investor
Co Invest
Number of exits
Preferred contact method

Portfolio

Synthetica (China)

HepaRegenix

Tacalyx

Asgard Therapeutics

Obulytix

Glox Therapeutics

Smartbax

Diogenx

Cmo Medical Solutions

Rewind Therapeu

Cardior

Metabomed

T3 Pharmaceuticals

Aelin Therapeutics

Anagenesis Biotechnologies

OncoMyx Therapeutics

Abexxa Biologics

NBE Therapeutics

ArmaGen

Amal Therapeutics

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp